{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '9301 Amberglen Boulevard',
 'address2': 'Suite 100',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.79,
 'askSize': 800,
 'averageDailyVolume10Day': 876850,
 'averageVolume': 444046,
 'averageVolume10days': 876850,
 'beta': 1.705117,
 'beta3Year': None,
 'bid': 11.71,
 'bidSize': 1400,
 'bookValue': 1.833,
 'category': None,
 'circulatingSupply': None,
 'city': 'Austin',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.51,
 'dayLow': 11.87,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.329,
 'enterpriseToRevenue': 23.557,
 'enterpriseValue': 457083040,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.847428,
 'fiftyTwoWeekHigh': 19.12,
 'fiftyTwoWeekLow': 4.51,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27823243,
 'forwardEps': -1.92,
 'forwardPE': -6.2239585,
 'fromCurrency': None,
 'fullTimeEmployees': 183,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.13763,
 'heldPercentInstitutions': 0.79491997,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1501632000,
 'lastSplitFactor': '1:11',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/mtem.com',
 'longBusinessSummary': 'Molecular Templates, Inc., a clinical stage oncology '
                        'company, focuses on the discovery and development of '
                        'biologic therapeutics for the treatment of cancer and '
                        'other diseases. The company primarily develops a '
                        'pipeline of engineered toxin bodies. Its lead drug '
                        'candidate is MT-3724 that is in a Phase II clinical '
                        'trial for the treatment of relapsed/refractory '
                        'diffuse large B-cell lymphoma; and Phase II clinical '
                        "trial for treating non-Hodgkin's lymphoma. The "
                        'company also develops MT-4019, engineered toxin body '
                        'targeting CD38; and TAK-169 targeting CD38. It has an '
                        'agreement with Takeda Pharmaceutical Company Limited '
                        'to develop CD38-targeted engineered toxin bodies for '
                        'the treatment of patients with diseases, such as '
                        'multiple myeloma; and a strategic research '
                        'collaboration with Vertex Pharmaceuticals '
                        'Incorporated to discover and develop novel targeted '
                        'conditioning regimens to enhance the hematopoietic '
                        'stem cell transplant process. Molecular Templates, '
                        'Inc. is headquartered in Austin, Texas.',
 'longName': 'Molecular Templates, Inc.',
 'market': 'us_market',
 'marketCap': 546477056,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_27892633',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -85271000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.46,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '512-869-1555',
 'previousClose': 12.54,
 'priceHint': 2,
 'priceToBook': 6.519367,
 'priceToSalesTrailing12Months': 28.164564,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.51,
 'regularMarketDayLow': 11.87,
 'regularMarketOpen': 12.46,
 'regularMarketPreviousClose': 12.54,
 'regularMarketPrice': 12.46,
 'regularMarketVolume': 173580,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45705600,
 'sharesPercentSharesOut': 0.035,
 'sharesShort': 1602735,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1195477,
 'shortName': 'Molecular Templates, Inc.',
 'shortPercentOfFloat': 0.0923,
 'shortRatio': 4.07,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'MTEM',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.132,
 'twoHundredDayAverage': 14.823022,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '50b78e85-ce75-3e81-80ea-f799bd42f2e1',
 'volume': 173580,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.mtem.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '78729'}